Lee's Pharmaceutical Holdings Limited

Equities

950

KYG5438W1116

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
1.19 HKD -1.65% Intraday chart for Lee's Pharmaceutical Holdings Limited -6.30% -22.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024 CI
Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Grants Lee's Pharmaceutical Drug Registration for Schizophrenia-Related Agitation Treatment; Shares Rise 3% MT
Lee’s Pharmaceutical Sells Rights for Eyprotor to Zhaoke Ophthalmology for 60 Million Yuan MT
Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 04 October 2023 CI
Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Lee's Pharmaceutical Holdings Unit's Fentanyl Inhalable Reaches Endpoints in Phase 2A Trial MT
Lee's Pharmaceutical Holdings Limited Announces Phase IIa Clinical Trial of A F fentanyl Aerosol for Inhalation Conducted by Zhaoke Pharmaceutical Limited CI
Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023 CI
Lee’s Pharmaceutical Gets Registration Certificate for Medical Device to Treat Hypoxic Respiratory Failure MT
Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director CI
Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 15 June 2023 CI
Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Lee’s Pharmaceutical Holdings Warns of Plunge in 2022 Profit MT
Lee's Pharmaceutical Holdings Limited Provides Group Earnings Guidance for the Year Ended 31 December 2022 CI
Extended Phase 2b Study for Lee's Pharmaceutical's Tafoxiparin Concludes; Shares Slip 3% MT
Nine Lee's Pharma Products Included in China's National Reimbursement Drug List MT
Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List CI
Lee's Pharmaceutical's Q3 Profit More Than Doubles MT
Lee’s Pharmaceutical Q3 Profit Jumps 150% MT
Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
US FDA Approves Lee's Pharmaceutical's Clinical Trial for Liver Cancer Treatment MT
Lee's Pharma Unit Completes Enrolment for Phase III Trial for Vulvovaginal Atrophy Treatment; Shares Climb 7% MT
Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa CI
Lee's Pharmaceutical to Sell Guangzhou Zhaokang Hospital for $28 Million MT
Chart Lee's Pharmaceutical Holdings Limited
More charts
Lee's Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacturing, marketing and sales of pharmaceutical products. The Company operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The Company's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The Company mainly operates its business in mainland China, Hong Kong and Taiwan.
More about the company
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
1.19 HKD
Average target price
1 HKD
Spread / Average Target
-15.97%
Consensus

Chiffre d''affaires - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Lee's Pharmaceutical Holdings Limited - Hong Kong S.E.
  4. News Lee's Pharmaceutical Holdings Limited
  5. Lee's Pharma Unit Completes Enrolment for Phase III Trial for Vulvovaginal Atrophy Treatment; Shares Climb 7%